Sequence verification: for an obscure compound, a report of the amino acid sequence or a mass-spectrometry result confirming the mass is the only verification that actually matters. A supplier's certificate stating the name is not verification.
Sequence verification for an obscure compound: how it is done — what changed since
Naming conventions for research peptides cause confusion because suppliers do not follow a standard. The same compound gets different names from different suppliers. If you are researching something, confirming the sequence or mass is more reliable than confirming the name.
Thank you for the correction. I have edited my earlier post with a note rather than silently, so the thread still makes sense to read. The error was mine and it was the kind that comes from remembering a figure instead of looking it up.
Why catalogue breadth is not evidence of anything: a supplier listing 500 compounds does not make the 450 untested ones likely to work. It makes them untested compounds with supplier pages.
Reading a supplier's product description as a marketing document: that is exactly what it is. The hyperbole, the mechanism written as fact, the theoretical benefits stated as established benefits — all of that is marketing. Treat it as such and separate it from evidence where evidence exists.
Coming back to post #66, because the follow-up matters more than the original answer.
Research-use-only status is a legal classification, not a safety classification. It means the compound is sold for laboratory use and not for human consumption or treatment. The label does not tell you whether the molecule is safe, efficacious, or what its effects are.
This follows post #73 rather than contradicting it.
For anyone arriving from a search: the marked solution above is the direct answer, and the replies underneath it add the caveats that make it safe to use.
Sequence verification: for an obscure compound, a report of the amino acid sequence or a mass-spectrometry result confirming the mass is the only verification that actually matters. A supplier's certificate stating the name is not verification.
Research-use-only status is a legal classification, not a safety classification. It means the compound is sold for laboratory use and not for human consumption or treatment. The label does not tell you whether the molecule is safe, efficacious, or what its effects are.
Read the full topic (109 posts)
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Naming conventions for research peptides and the confusion they cause — one year on
Naming conventions for research peptides and the confusion they cause — one year on — setting out what I have, and where I think it stops being reliable. I have seen SURMOUNT-2 ( Lancet , 2023) cited in…
|
+1 | 5 | 181 | 2y |
|
How to research a compound with no human data without deceiving yourself
Asking directly, because I could not find a straight answer: How to research a compound with no human data without deceiving yourself Session topic: STEP 2 ( Lancet , 2021). Please read it before posting; the…
|
+107 | 119 | 11k | 12mo |
|
Coming back to: Reading a supplier's product description as a marketing document
Reading a supplier's product description as a marketing document Writing it up because I had to work it out twice and would rather nobody else did. I have seen SUSTAIN 6 ( N Engl J Med , 2016) cited in…
|
+35 | 39 | 688 | 5mo |
|
Why catalogue breadth is not evidence of anything
Why catalogue breadth is not evidence of anything I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a claim I…
|
2 | 38k | 2d | |
|
Sequence verification for an obscure compound: how it is done
Sequence verification for an obscure compound: how it is done Writing it up because I had to work it out twice and would rather nobody else did. Comparing SUSTAIN 6 ( N Engl J Med , 2016) with SURMOUNT-1 ( N…
|
+104 | 114 | 10k | 12mo |
Related topics — sharing the tags custom synthesis, needs a source, mislabelling
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Conference abstracts as evidence: the weakest common citation
On the subject in the title: Conference abstracts as evidence: the weakest common citation Working notes rather than a conclusion. Session topic: SURMOUNT-1 ( N Engl J Med , 2022). Please read it before…
|
+1 | 5 | 2k | 9mo |
|
A widely repeated interaction claim that turns out to be unsupported
On the subject in the title: A widely repeated interaction claim that turns out to be unsupported Working notes rather than a conclusion. Practical question with the units stated, because I have seen how…
|
+47 | 51 | 37k | 3mo |
|
GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion
On the subject in the title: GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion Working notes rather than a conclusion. I have seen STEP 2 ( Lancet , 2021) cited in support of…
|
+47 | 53 | 6.9k | 2h |
|
Preprint servers and what screening they do
Preprint servers and what screening they do — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a claim I do not think it…
|
+95 | 106 | 5.6k | 4mo |
|
Reading a rodent study on a secretagogue without over-extrapolating — the long version
Reading a rodent study on a secretagogue without over-extrapolating — the long version — setting out what I have, and where I think it stops being reliable. I have seen STEP 4 ( JAMA , 2021) cited in support…
|
+59 | 66 | 30k | 4h |